A long-term term reduction of breast cancer incidence for anastrozole or any aromatase inhibitor has not been established, as it has for tamoxifen.2, 3 Such a result is likely to substantially improve the benefit-risk ratio, as side-effects are uncommon after treatment cessation. The gene discussed is CYP19A1; the disease is breast cancer.